Title
[¹⁸F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity.

Permalink
https://escholarship.org/uc/item/5df0b26k

Journal
Proceedings of the National Academy of Sciences of the United States of America, 113(15)

ISSN
0027-8424

Authors
Kim, Woosuk
Le, Thuc M
Wei, Liu
et al.

Publication Date
2016-04-01

DOI
10.1073/pnas.1524212113

Peer reviewed
Deoxycytidine kinase (dCK), a rate-limiting enzyme in the cytosolic deoxyribonucleoside (dN) salvage pathway, is an important therapeutic and positron emission tomography (PET) imaging target in cancer. PET probes for dCK have been developed and are effective in mice but have suboptimal specificity and sensitivity in humans. To identify a more suitable probe for clinical dCK PET imaging, we compared the selectivity of two candidate compounds—[18F]Clofarabine; 2-chloro-2-deoxy-2-[[18F]fluoro-9-β-D-arabinofuranosyl]-adenine ([18F]CFA) and 2’-deoxy-2-[[18F]fluoro-9-β-D-arabinofuranosylguanine ([18F]-AraG)—for dCK and deoxyguanosine kinase (dGK), a dCK-related mitochondrial enzyme. We demonstrate that, in the tracer concentration range used for PET imaging, [18F]CFA is primarily a substrate for dCK, with minimal cross-reactivity. In contrast, [18F]-AraG is a better substrate for dGK than for dCK. [18F]CFA accumulation in leukemia cells correlated with dCK expression and was abrogated by treatment with a dCK inhibitor. Although [18F]CFA uptake was reduced by deoxycytidine (dC) competition, this inhibition required high dC concentrations present in murine but not human, plasma. Expression of cytidine deaminase, a dC-catabolizing enzyme, in leukemia cells both in cell culture and in mice reduced the competition between dC and [18F]CFA, leading to increased dCK-dependent probe accumulation. First-in-human, to our knowledge, [18F]CFA PET/CT studies showed probe accumulation in tissues with high dCK expression: e.g., hematopoietic bone marrow and secondary lymphoid organs. The selectivity of [18F]CFA for dCK and its favorable biodistribution in humans justify further studies to validate [18F]CFA PET as a new cancer biomarker for treatment stratification and monitoring.

Accurate DNA replication and repair require sufficient and balanced production of deoxyribonucleoside triphosphates (dNTPs) (1). Mammalian cells synthesize dNTPs by two biochemical routes: the de novo pathway produces dNTPs from glucose and amino acid precursors whereas the nucleoside salvage pathway generates dNTPs from deoxyribonucleosides (dNs) scavenged from the extracellular milieu by the combined action of nucleoside transporters and dN kinases (Fig. S1A). The cytosolic dN kinases in mammalian cells are thymidine kinase 1 (TK1), which phosphorylates thymidine (dT) and deoxyuridine (dU), and deoxycytidine kinase (dCK), which phosphorylates deoxycytidine (dC), deoxyadenosine (dA), and deoxyguanosine (dG) (2). Although dCK has been studied extensively in vitro, its in vivo functions are not well understood. Previously, we reported impaired hematopoiesis in dCK−/− mice resulting from DNA replication stress in hematopoietic progenitors due to insufficient dCTP supply (3, 4). More recently, we showed that, in cancer cells, dCK confers resistance to inhibitors of de novo dCTP biosynthesis and that pharmacological cotargeting of dCK and ribonucleotide reductase, the rate-limiting enzyme in the de novo pathway, was well-tolerated and efficacious in animal models of acute leukemia (5, 6). dCK also plays an essential role in the activation of the nucleoside analog prodrugs Cytarabine, Fludarabine, Gemcitabine, Fludarabine phosphate, Cladribine, Clofarabine, and AraC (7) (Fig. S1B). Clinically applicable assays to measure tumor dCK activity in vivo would be of great value, given the variable response rates and toxicities associated with these frequently used prodrugs (7). Collectively, the identification of dCK as a new therapeutic target in acute
leukemia, the requirement for dCK in the activation of FDA-approved nucleoside analog prodrugs, and the heterogeneous expression of dCK in cancer suggest that dCK is an important target for noninvasive biomarker PET imaging.

The first PET probe described for dCK imaging was 1-(2'-deoxy-2'-[18F]fluoro-β-D-arabinofuranosyl)cytosine ([18F]FAC) (8). Although [18F]FAC enabled PET imaging of dCK activity in mice (8–11), a subsequent study (12) questioned its clinical utility because of rapid probe catabolism mediated by cytidine deaminase (CDA), an enzyme present at higher levels in humans than in rodents (13). CDA converts [18F]FAC to 1-(2’-deoxy-2’-[18F]fluoro-β-D-arabinofuranosyl)uracil ([18F]FAU), a metabolite that is not phosphorylated by dCK. To overcome this problem, t-enantiomer analogs of [18F]FAC that resisted deamination and retained affinity for dCK were developed (14). Two of the t-enantiomer analogs—1-(2’-deoxy-2’-[18F]fluoro-β-D-arabinofuranosyl)cytosine (1-(18F)FAC) and 2’-deoxy-2’-[18F]fluoro-5-methyl-β-D-arabinofuranosylcytosine (1-(18F)FMAC)—were translated to the clinic (12, 15). These second generation dCK probes had better sensitivity than [18F]FAC in humans as reflected by improved accumulation in the bone marrow, a tissue with high dCK activity. However, both [18F]FAC analogs were cross-reactive with mitochondrial thymidine kinase 2 (TK2), which, like dCK, lacks enantioselectivity and consequent phosphorylates deoxypurines with both t- and t-enantiomeric configurations (16). In humans, cross-reactivity with TK2 was likely responsible for the uptake of the FAC analogs into the myocardiun (12), a tissue with high TK2 expression (17).

Because dCK phosphorylates both pyrimidines and purines (18), the limitations of current PET probes for dCK could be circumvented using fluorinated purine analogs. Two candidate purine PET probes for dCK have been proposed (Fig. 1A): [18F]Clofarabine; 2-chloro-2’-deoxy-2’-[18F]fluoro-9-β-D-arabinofuranosyl-adenine ([18F]F-AraG) (14) and 2’-deoxy-2’-[18F]fluoro-9-β-D-arabinofuranosyl-guanine ([18F]FAU) (19). Unlike FAC and its analogs, neither of these purine analogs is phosphorylated by TK2. However, both [18F]F-AraG and [18F]FAU may be substrates for the mitochondrial deoxyguanosine kinase (dGK) (Fig. 1A), which is structurally related to both dCK and TK2 (20). Despite some overlap in substrate specificity, dCK and dGK have distinct biological functions (18, 21, 22) and expression patterns (23). Therefore, to properly interpret the information provided by [18F]F-AraG and [18F]FAU PET scans, it is essential to delineate the roles played by dCK and dGK in the intracellular trapping of these two candidate PET probes. Here, we compared the selectivity of [18F]F-AraG and [18F]FAU for dCK and dGK. Observed differences in kinase selectivity indicated that PET assays using these probes are likely to have distinct applications, with [18F]F-AraG as the choice for clinical dCK imaging and [18F]FAU as the appropriate probe for dGK imaging. We then investigated whether competition between [18F]F-AraG and endogenous dC affected the sensitivity of [18F]F-AraG PET imaging in the range of plasma dC concentrations found in mice, humans, and other species. We also present preliminary first-in-human, to our knowledge, studies of [18F]F-AraG biodistribution and discuss how this tracer complements the current repertoire of PET probes for nucleotide metabolism.

**Results**

**Differential Selectivity of [18F]F-AraG and [18F]FAU for dCK and dGK.** To determine the selectivity of [18F]F-AraG and [18F]FAU for dCK and dGK, CEM-R leukemia cells, which do not express dCK (24) but can contain endogenous dGK (Fig. 1B), were reconstituted with human dCK (CEM-R-dCK) (Fig. 1B). To enable an additional comparison between [18F]F-AraG and [18F]FAU in the absence of any confounding aspects related to potential differences in the access of these two probes to mitochondrial-located dGK, we also generated CEM-R cells that express a truncated form of human dGK (CEM-R-ΔdGK), which lacks the N-terminal mitochondrial sorting signal (Fig. 1B). CEM-R cells expressing enhanced yellow fluorescent protein (CEM-R-EYFP) completed the isogenic panel (Fig. 1B). Radioactive uptake
assays using tracer amounts (10–100 nM) of \([^{3}H]\)-labeled endogenous substrates deoxycytidine (\([^{3}H]dC\)) and deoxyguanosine (\([^{3}H]dG\)) were used to validate the isogenic lines. \([^{3}H]dC\) accumulation was 237 ± 17-fold higher in CEM-R-dCK cells compared with CEM-R-EYFP and CEM-R-ΔdGK cells (Fig. 1C). DI-82, a specific dCK inhibitor (25), abrogated \([^{3}H]dC\) accumulation in CEM-R-dCK cells (Fig. 1C). CEM-R-ΔdGK cells retained 6.62 ± 0.49-fold more \([^{3}H]dG\) compared with CEM-R-EYFP cells (Fig. 1D), thereby confirming the functionality of the truncated dGK construct. \([^{3}H]dG\) also accumulated in CEM-R-dCK cells (2.01 ± 0.19-fold increase relative to CEM-R-EYFP cells) (Fig. 1D), consistent with the ability of dCK to phosphorylate both pyrimidine and purine substrates (2, 18). The isogenic CEM-R panel was then used to compare the accumulation of tracer amounts (50–100 μM) of \([^{18}F]\)CFA and \([^{18}F]\)FLT accumulation in CEM-R-EYFP cells was indistinguishable from background levels (Fig. 1E). Although ΔdGK overexpression resulted in a minor increase (2.97 ± 0.09-fold) in \([^{18}F]\)CFA accumulation, a much larger (79 ± 2-fold) increase in probe uptake was observed in the CEM-R-dCK cells (Fig. 1E). DI-82 abrogated \([^{18}F]\)CFA accumulation in CEM-R-dCK cells (Fig. 1E), thereby confirming the specificity of this probe for dCK. Overall, \([^{18}F]\)CFA accumulation in the isogenic CEM-R panel closely resembled that of \([^{3}H]dC\) (Fig. 1C). In contrast, \([^{18}F]\)Ar-AraG accumulation (Fig. 1F) closely resembled that of \([^{3}H]dG\) (Fig. 1D). In summary, in the sub-nanomolar concentration range relevant for PET imaging, \([^{18}F]\)CFA is primarily a substrate for dCK, with minimal cross-reactivity for dGK, whereas \([^{18}F]\)Ar-AraG is primarily a substrate for dGK, with dCK playing a lesser role. \([^{18}F]\)CFA accumulation was sensitive to variations in dCK expression (Fig. 1G and H), further supporting the utility of this probe for imaging dCK activity.

**[\(^{18}F\)]CFA Accumulation Is Inhibited by Deoxycytidine at Concentrations Present in Murine and Rat Plasma, but Not in Human or Nonhuman Primate Plasma.** Competition between probes and endogenous metabolites often reduces the sensitivity of PET assays: e.g., 2-deoxy-2-[\(^{18}F\)]fluoro-D-glucose (\([^{18}F]FDG\)) competes with endogenous glucose (26) and 3-[\(^{18}F\)]fluoro-3-deoxythymidine (\([^{18}F]FLT\)) competes with endogenous thymidine (dT) (27, 28). As shown in Fig. 2A, \([^{18}F]\)CFA accumulation is also inhibited in a dose-dependent manner by dC, the physiological substrate of dCK, with an IC\(_{50}\) value of 181 ± 56 nM (Fig. 2A). Deoxyadenosine (dA) and deoxyguanosine (dG), which are also dCK substrates (18), also inhibited \([^{18}F]\)CFA accumulation (Fig. S2). The high IC\(_{50}\) values observed for dA and dG (75 μM and 33 μM, respectively) (Fig. S2) likely reflect the rapid catabolism of these purine dNs by adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP); both are expressed at high levels in lymphoid cells (29, 30).

To determine whether the competition between CFA and dC observed in cell culture could also occur in vivo, plasma dC levels in humans, nonhuman primates (NHPs), mice, and rats were measured by combined liquid chromatography tandem mass spectrometry in the multiple reaction-monitoring mode (LC-MS/MS-MRM) (Fig. 2B). C57BL/6 mouse and rat plasma dC concentrations were in the high nanomolar to low micromolar range, which, according to our cell culture data, are sufficient to inhibit CFA uptake. In marked contrast, plasma dC concentrations were two to three orders of magnitude lower in humans and NHPs than in mice and rats and are well-below the levels that can inhibit CFA uptake. A similar pattern was observed for dT in our study (Fig. 2C), in agreement with previous reports (31, 32). In contrast to dC and dT, plasma concentrations of dA and dG did not differ significantly in the examined species (Fig. 2D and E). Mouse plasma dN levels were not affected by 24-h fasting (Fig. 2F), arguing against an exogenous origin for these nucleosides. Instead, the observed differences are likely the result of different catabolic rates of endogenously produced dC and dT in rodents vs. primates. To test this hypothesis, stable isotope-labeled dC ([\(^{13}C\)\(_6\),\(^{15}N\)\(_2\)]dC) was incubated for 1 h in human plasma with or without tetrahydrodizuridine (THU), a specific cytidine deaminase (CD) inhibitor (33). CD catalyzes the first step in cd catabolism by converting CFA to deoxyuridine (dU). LC-MS/MS-MRM analyses of labeled dC and dU demonstrated that dC was catabolized more rapidly in human than in murine plasma (Fig. 2G, Top and Bottom). Moreover, the CD inhibitor THU blocked dC deamination in human plasma (Fig. 2G, Middle).

To further investigate how CD expression influences CFA accumulation, CEM cells engineered to express CD (CEM-CD) or EYFP (CEM-EYFP, negative control) (Fig. 3) were incubated with cell culture medium containing 5 μM [\(^{13}C\)\(_6\),\(^{15}N\)\(_2\)]dC. The medium was sampled at the times shown to measure the CD- and THU-mediated catabolism of labeled dC. An ∼32-fold decrease in the amount of [\(^{13}C\)\(_6\),\(^{15}N\)\(_2\)]dC was observed after a 6 h incubation with CEM-CD cells, but not with the CD-negative
cells (Fig. 3B). Consequently, [3H]CFA added for 1 h after the 6-h incubation period was retained only in the CEM-CDA cells. [3H]CFA accumulation by the CEM-CDA cells was dCK-dependent, as indicated by the effect of the dCK inhibitor DI-82 (Fig. 3C). To model these cell culture findings in vivo, nonobese diabetic (NOD) SCID IL-2 receptor gamma chain KO (NSG) mice underwent s.c. bilateral implantation with either CEM-EYFP or CEM-CDA cells in both flanks. Mice bearing bilateral tumors were imaged serially by PET/CT, using either [18F]CFA or [18F]FDG, at the indicated times (Fig. 4A). Plasma dC concentrations decreased with time in mice with CEM-CDA tumors but not in mice with CEM-EYFP tumors (Fig. 4B), likely reflecting the leakage of tumor CDA in plasma. Consistent with the cell culture data (Fig. 3C), mice bearing CEM-CDA tumors, which had reduced plasma dC levels, accumulated significantly more [18F]CFA than mice bearing CEM-EYFP tumors, as indicated by day 17 PET scans (Fig. 4 C and D). [18F]FDG PET scans performed on day 18 revealed similar metabolic activity in both CDA and EYFP tumors (Fig. 4 C and E). On day 19, mice were treated with DI-82 followed by a second [18F]CFA PET scan, which confirmed that tumor probe accumulation was dCK-dependent (Fig. 4 C and D). Collectively, these data indicate that (i) competition with endogenous dC reduces the sensitivity of [18F]CFA PET imaging in species with high levels of plasma dC concentration such as mice and rats, (ii) CDA activity is an important determinant of [18F]CFA accumulation in tumors, by reducing the levels of competing endogenous dC, and (iii) tumor [18F]CFA accumulation in vivo requires dCK activity.

First-in-Human [18F]CFA Biodistribution Studies. Because dC competes with CFA for cellular uptake (Fig. 2A) and because plasma dC levels are two to three orders of magnitude lower in humans than in mice (Fig. 2B), we hypothesized that the biodistribution of [18F]CFA will be more favorable in humans than in mice. Indeed, unlike the negative scans in mice (14), [18F]CFA PET/CT scans in healthy volunteers revealed significant probe accumulation in dCK-positive tissues (bone marrow, liver, and spleen) (Fig. 5A). [18F]CFA also accumulated in the axillary lymph nodes (Fig. 5A, arrows) of healthy volunteers (Fig. 5A, Left, coronal; Right, transverse image). Label accumulation in the kidneys and bladder was indicative of urinary clearance. [18F]CFA and [18F]FDG PET/CT scans of a paraganglioma patient showed label accumulation in a skull bone tumor lesion but not in a lumbar vertebra bone lesion (Fig. 5B), reflecting interlesion heterogeneity in [18F]CFA uptake. We were initially surprised that the [18F]CFA accumulation observed throughout the spinal column in healthy volunteers (Fig. 5A) was not detected in the paraganglioma patient in whom the lumbar segment of the spinal column was negative for [18F]CFA accumulation (Fig. 5C). A subsequent examination of the clinical history of this patient revealed that the [18F]CFA-negative spine

---

**Fig. 3.** Increased CDA expression reduces dC levels and increases [3H]CFA accumulation by CEM leukemia cells. (A) Western Blot for CDA expression in CEM cells engineered to express EYFP or CDA. (B) LC-MS/MS-MRM measurements of dC levels in culture supernatants from these cells incubated for the indicated times with 5 μM [U-13C2,15N]dC. n = 3. (C) [3H]CFA (9.25 kBq) uptake (over 1 h) in the isogenic panel described in A, after 6 h of incubation in medium supplemented with dC (5 μM) ± DI-82 (1 μM). N.S., nonsignificant; ***P < 0.001. Results are representative of three independent experiments (n = 3 for each group).

---

**Fig. 4.** Increased CDA expression in tumor xenografts is sufficient to reduce plasma dC levels in mice and to increase dCK-dependent tumor [18F]CFA accumulation. (A) Experimental design and timeline. (B) Plasma dC levels in tumor-bearing mice were measured at the indicated times. On day 20 post-tumor inoculation, plasma dC concentration in the NSG mice injected with CEM-CDA cells was below 10 nM (gray circle), which corresponds to the lowest limit of detection of the LC-MS/MS-MRM assay. ***P < 0.001; n = 5 mice per group. (C) Representative PET/CT scans of a mouse that was serially imaged with [18F]CFA (day 17), with [18F]FDG (day 18), and then again with [18F]CFA on day 19, 2 h after treatment with DI-82 (50 mg/kg in 50% PEG/Tris, pH 7.4, i.p. injection). GB, gallbladder; H, heart; %ID/g, percentage injected dose per gram; T, tumor. (D and E) Quantification of [18F]CFA and [18F]FDG PET/CT scans from C. N.S., nonsignificant; **P < 0.01; n = 5 mice per group.
region corresponds anatomically to the part of the vertebral column that was previously (9 mo before the scan) irradiated to target a tumor lesion at this location. This serendipitous finding suggested that $^{18}$F-CFA bone accumulation in humans likely reflects dCK-dependent probe uptake by bone marrow cells, rather than probe defluorination. Further supporting this interpretation, CFA defluorination was not detected in metabolic stability studies of CFA administered at pharmacological doses in humans (34).

**Discussion**

We show that $^{18}$F-CFA is a highly specific substrate/probe for dCK, with minimal cross-reactivity with dGK. $^{18}$F-CFA accumulation in leukemia cells was competitively inhibited in a concentration-dependent manner by dC, the physiological dCK substrate. Evidence is provided that plasma dC levels vary significantly across species and that these variations correspond to striking differences in $^{18}$F-CFA biodistribution between mice and humans. Accordingly, the $^{18}$F-CFA PET assay is more sensitive in humans than in mice, due to reduced competition between the probe and endogenous dC. $^{18}$F-CFA accumulation in leukemia cells was dCK-dependent, and probe accumulation was sensitive to variations in dCK expression. In this context, a large variation in dCK expression and activity was observed in a panel of lymphoma cell lines (35). Similar variations in dCK expression likely occur in other cancers. dC mRNA levels also increase upon T-cell activation (8). Additional levels of dCK regulation involve posttranslational mechanisms. For example, phosphorylation of dCK at Ser-74 increases dCK activity (36). The DNA-damage response kinase Ataxia-telangiectasia mutated (ATM) has been proposed to catalyze this dCK phosphorylation (36–38). If the observed sensitivity of $^{18}$F-CFA PET to variations in dCK activity is confirmed by larger clinical studies, this noninvasive, real-time PET assay may provide a useful biomarker for various therapies that trigger T-cell activation, induce DNA damage (36), or rely on dCK-dependent nucleoside analog prodrugs. In particular, $^{18}$F-CFA may be useful as a pharmacokinetic PET stratification biomarker for its corresponding drug Clofarabine (Clolar; Genzyme) (39). Furthermore, as dCK inhibitors (5, 6, 25) advance toward clinical trials, $^{18}$F-CFA PET could provide a companion pharmacodynamic biomarker to help optimize dosing and scheduling regimes.

Given the susceptibility of $^{18}$F-CFA uptake to competition by endogenous nucleosides, the use of $^{18}$F-CFA in patients with elevated plasma dN levels may result in false-negative scans. Such conditions include the tumor lysis syndrome that follows chemotherapy in hematological malignancies (40), genetic defects in the purine nucleoside-catabolizing enzymes adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) (41, 42), and treatment of certain leukemias with ADA and PNP inhibitors (43, 44). In addition to plasma dN levels, which should be determined in each patient scanned with $^{18}$F-CFA, the interpretation of $^{18}$F-CFA PET scans should also take into account factors other than dCK that could modulate probe accumulation. Both concentrative and equilibrative nucleoside transporters, as well as ATP-binding cassette (ABC) transporters, could all modulate $^{18}$F-CFA accumulation in tumors (45, 46).

In summary, this work supports the evaluation of $^{18}$F-CFA in larger clinical studies as a companion biomarker for multiple therapeutic approaches. Moreover, $^{18}$F-CFA complements the toolbox of nucleoside analog PET probes for imaging dN kinases (Fig. 6). Given the diverse biological functions and the therapeutic relevance of cytosolic and mitochondrial dN kinases, the availability of a toolbox of PET imaging probes to noninvasively measure the activity of these enzymes could enable a wide range of preclinical and clinical applications.

**Materials and Methods**

LC-MS/MS-MRM. Details of LC-MS/MS-MRM analyses are provided in SI Materials and Methods.

Immunoblotting. Immunoblotting was performed as previously described (4). Primary and secondary antibodies are provided in SI Materials and Methods.

Animal Studies. Animal studies were conducted under the approval of the UCLA Animal Research Committee and were performed in accordance with the guidelines from the Division of Laboratory Animal Medicine at UCLA. For tumor xenograft experiments, 2 × 10⁶ CEM-EYFP and CEM-CDA were resuspended in 100 μL of a 50/50 (vol/vol) mixture of PBS and matrigel (BD Biosciences) for s.c. injections in the left and right shoulders of NSG mice.

**Cell-Based Uptake Assays Using Radioactive Probes.** Uptake assays were conducted as previously described (47). See details in SI Materials and Methods.

![Diagram](image-url)

**Fig. 5.** $^{18}$F-CFA PET CT images in humans. (A) Images of $^{18}$F-CFA biodistribution in a healthy volunteer. Maximum intensity 2D projection whole body image (Left) and cross-sectional tomographic image (Right) of the axilla indicating probe accumulation in the lymph nodes. (B) $^{18}$F-CFA PET/CT and $^{18}$F-FDG PET/CT images of a paraganglioma patient showing variability in $^{18}$F-CFA accumulation between the skull lesion and the vertebra lesion. (C) Whole body $^{18}$F-CFA image of the same patient as in B, showing reduced probe accumulation in previously irradiated lumbar spine region.

![Diagram](image-url)

**Fig. 6.** The current toolbox of PET probes for nucleotide metabolism. Proposed matching of PET probes with deoxyribonucleoside salvage kinases. $^{18}$F-FLT, 3′-d$^{18}$F-fluoro-3′-deoxythymidine (48); 1′-d$^{18}$F-FMAU, 2′-deoxy-2′-d$^{18}$F-fluoro-5-methyl-1′-β-D-arabinofuranosyluracil (47, 49); d$^{18}$F-FMAU, 2′-deoxy-2′-d$^{18}$F-fluoro-5-methyl-1′-β-D-arabinofuranosyluracil (50, 51). Potential applications for these probes, as well as anatomical sites of preferential accumulation in healthy volunteers, are indicated. *, $^{18}$F-FLT accumulation in the liver reflects probe glucuronidation (52). N.D., not determined; PD, pharmacodynamic; PK, pharmacokinetic. **, $^{18}$F-Ara-G uptake may also reflect dCK activity.
Additional experimental details are described in SI Materials and Methods.

2. Sabini E, Hazra S, S on, K onrad M, Lavie A (2008) Structural basis for substrate pro-
13. Ho DH (1973) Distribution of kinase and deaminase of 1-beta-D-arabinofur-
17. Kamath VG, Hsiung CH, Lizenby ZJ, McKee EE (2015) Heart mitochondrial TTP synth-
ase expression is reduced in type 2 diabetes mellitus. Diabetes Care 320(9):1811–1818.
23. Ho DH (1973) Distribution of kinase and deaminase of 1-beta-D-arabinofur-
27. Ho DH (1973) Distribution of kinase and deaminase of 1-beta-D-arabinofur-